Collaborate with usWhat’s new?
Products on our platform

Evidence-based, high-impact 
software as medicine.

Click’s platform can target any disease, symptom or side effect with an underlying neurological or behavioral component, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases.

Product

Indication

Collaborator

Phase

Click SE

Medicine just got a digital upgrade: Software-Enhanced Drugs™

Click SE™ solutions combine software with pharmacotherapy to create software-enhanced drug™ treatments, to deliver added clinical benefit to patients compared to drug alone.

Discover Click SE

Contact

Join us in our journey to raise the bar of modern medicine with software as treatments.
Join us

Q&A

Stay up to date with news and updates

CT-152

CT-152

Rejoyn

Indication

Major Depressive Disorder (MDD)

Collaborator

Otsuka Pharmaceutical

Phase

Launch

Developed in collaboration with Otsuka, Rejoyn (CT-152) is the first prescription digital therapeutic to receive FDA clearance for the treatment of Major Depressive Disorder (MDD) symptoms. 

Rejoyn is a six-week treatment program designed to help enhance cognitive control of emotion through a combination of clinically-validated cognitive emotional training exercises for the brain and brief therapeutic lessons. Unlike wellness apps, the Rejoyn app is a medical device authorized by the FDA for prescription by a healthcare professional. 

Rejoyn introduces clinically-validated cognitive emotional brain training exercises (“Emotional Faces Memory Task” or “EFMT”) that were developed and studied by a team of psychologists, psychiatrists and neuroscientists. These brain exercises are designed to target and help alter those neural connections necessary to appropriately process emotions with the goal of reducing symptoms of depression.

Indication: Rejoyn is a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. It is intended to reduce MDD symptoms.

Read more on Rejoyn.com

Rejoyn Data

Individuals treated with Rejoyn showed an improvement in depression symptom severity from baseline.

Symptom improvement was consistently observed across multiple patient and clinician-reported scales, including the Montgomery-Åsberg Depression Rating Scale (MADRS), Patient Health Questionnaire nine-item depression scale (PHQ-9), and the Clinical Global Impression – Severity scale (CGI-S). 

One month after completing the six-week treatment program, participants in the Rejoyn group showed continued improvement. No side effects were assessed as related to Rejoyn during the trial. Full clinical data may be found as part of the Clinician Brief Summary.

Safety Information

Rejoyn is not intended to be used as a standalone therapy or a substitute for medication. Patients should continue their current treatment as directed.

Rejoyn does not monitor the patient's symptoms or clinical status and cannot send or receive alerts or warnings to the prescriber. Patients should be clearly instructed that if they believe their depression is worsening or if they have feelings or thoughts of harming themselves or others, to contact a healthcare professional, dial 911 or go to the nearest emergency room immediately.

Publications

Rejoyn Screen
CT-152

CT-152

Rejoyn

Indication

Major Depressive Disorder (MDD)

Collaborator

Otsuka Pharmaceutical

Phase

Launch

Developed in collaboration with Otsuka, Rejoyn (CT-152) is the first prescription digital therapeutic to receive FDA clearance for the treatment of Major Depressive Disorder (MDD) symptoms. 

Rejoyn is a six-week treatment program designed to help enhance cognitive control of emotion through a combination of clinically-validated cognitive emotional training exercises for the brain and brief therapeutic lessons. Unlike wellness apps, the Rejoyn app is a medical device authorized by the FDA for prescription by a healthcare professional. 

Rejoyn introduces clinically-validated cognitive emotional brain training exercises (“Emotional Faces Memory Task” or “EFMT”) that were developed and studied by a team of psychologists, psychiatrists and neuroscientists. These brain exercises are designed to target and help alter those neural connections necessary to appropriately process emotions with the goal of reducing symptoms of depression.

Indication: Rejoyn is a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. It is intended to reduce MDD symptoms.

Read more on Rejoyn.com

Rejoyn Data

Individuals treated with Rejoyn showed an improvement in depression symptom severity from baseline.

Symptom improvement was consistently observed across multiple patient and clinician-reported scales, including the Montgomery-Åsberg Depression Rating Scale (MADRS), Patient Health Questionnaire nine-item depression scale (PHQ-9), and the Clinical Global Impression – Severity scale (CGI-S). 

One month after completing the six-week treatment program, participants in the Rejoyn group showed continued improvement. No side effects were assessed as related to Rejoyn during the trial. Full clinical data may be found as part of the Clinician Brief Summary.

Safety Information

Rejoyn is not intended to be used as a standalone therapy or a substitute for medication. Patients should continue their current treatment as directed.

Rejoyn does not monitor the patient's symptoms or clinical status and cannot send or receive alerts or warnings to the prescriber. Patients should be clearly instructed that if they believe their depression is worsening or if they have feelings or thoughts of harming themselves or others, to contact a healthcare professional, dial 911 or go to the nearest emergency room immediately.

Publications

Rejoyn Screen